Premium
Dual‐Stimuli‐Responsive Paclitaxel Delivery Nanosystems from Chemically Conjugate Self‐Assemblies for Carcinoma Treatment
Author(s) -
Xu JingWen,
Ge Xin,
Lv LiHua,
Xu Feng,
Luo YanLing
Publication year - 2018
Publication title -
macromolecular rapid communications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.348
H-Index - 154
eISSN - 1521-3927
pISSN - 1022-1336
DOI - 10.1002/marc.201800628
Subject(s) - paclitaxel , conjugate , chemistry , drug delivery , cytotoxicity , micelle , bromide , in vivo , combinatorial chemistry , drug carrier , aqueous solution , mtt assay , biophysics , materials science , in vitro , organic chemistry , biochemistry , chemotherapy , medicine , mathematical analysis , surgery , mathematics , microbiology and biotechnology , biology
Diselenide‐bond‐linked poly( N ‐isopropylacrylamide)‐paclitaxel chemical conjugates are synthesized as a drug release carrier. The conjugates can self‐assemble into “core–shell” nanoscaled micelles in aqueous solution and show thermal and redox dual‐responsiveness. The conjugates can afford a high encapsulation efficiency of up to 72.3%, and deliver hydrophobic anticancer drug paclitaxel in a temperature and oxidization or reduction stress‐mode. The in vitro 3‐(4,5‐dimethyl‐2‐thiazolyl)‐2,5‐diphenyl‐2‐H‐tetrazolium bromide (MTT) and in vivo anticancer assays are performed to assess the cytotoxicity and anticancer activity of the conjugates, suggesting that the developed conjugates can be used to treat carcinoma as a novel and highly efficient drug delivery system.